Common Peptide Side Effects
Comprehensive overview of side effects across major peptide classes, incidence rates from clinical trials, and evidence quality assessment.
Explore →Injection Site Reactions Explained
Understanding localized injection site effects, infection risk mitigation, proper injection technique, and when reactions may indicate complications.
Explore →GLP-1 Side Effects Comparison
Detailed side effect comparison across semaglutide, tirzepatide, and retatrutide, including incidence data from clinical trials and management strategies.
Explore →SubQ vs IM Injections
Comparing administration routes: subcutaneous versus intramuscular injection safety profiles, absorption differences, and systemic effects.
Coming Soon Coming SoonUnderstanding Peptide Purity & COA Reports
How to read Certificates of Analysis, interpreting purity standards, identifying contaminants that may affect safety profiles.
Coming Soon Coming SoonWhen to Discontinue a Peptide Protocol
Recognizing adverse events requiring discontinuation, managing side effects versus stopping treatment, and safe washout periods.
Explore →Why Safety Information Matters
Peptides represent a diverse class of molecules with varying safety profiles based on clinical evidence availability. GLP-1 receptor agonists have extensive safety data from large randomized controlled trials. Growth hormone secretagogues have moderate clinical evidence. Tissue repair and immune-modulating peptides often lack robust human safety data, making risk assessment more challenging.
This hub organizes safety information by peptide class, highlighting the distinction between:
- FDA-approved peptides with extensive post-market surveillance data
- Peptides in clinical development with Phase 2-3 trial data
- Research peptides with limited or primarily preclinical evidence
Understanding these distinctions is critical for informed decision-making regarding peptide use.